Five-day 4′-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia

This publication has 41 references indexed in Scilit:

• Intermediate-Dose Ara-C/m-AMSA for Remission Induction and High-Dose Ara-C/m-AMSA for Intensive Consolidation in Relapsed and Refractory Adult Acute Myelogeneous Leukemia
  Published by Springer Nature ,1990
• Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC leukemia cooperative group phase II study
  European Journal of Cancer and Clinical Oncology, 1988
• Results of induction and consolidation treatment with intermediate and high‐dose cytosine arabinoside and m‐Amsa of patients with poor‐risk acute myelogeneous leukaemia
  European Journal of Haematology, 1988
• Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia
  The American Journal of Medicine, 1986
• Lithotripsy
  Annals of Internal Medicine, 1985
• The use of intermediate dose cytosine arabinoside (ID Ara‐C) in the treatment of acute non‐lymphocytic leukaemia in relapse
  British Journal of Haematology, 1984
• High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma
  Cancer Chemotherapy and Pharmacology, 1984
• Amsacrine (AMSA)
  Cancer Treatment Reviews, 1980
• Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group
  British Journal of Haematology, 1976
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958